Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing

Anthrax vaccine adsorbed (AVA, BioThrax) was recently approved by the Food and Drug Administration (FDA) for a post-exposure prophylaxis (PEP) indication in adults 18–65 years of age. The schedule is three doses administered subcutaneous (SC) at 2-week intervals (0, 2, and 4 weeks), in conjunction w...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine
Main Authors: Stark, G.V., Sivko, G.S., VanRaden, M., Schiffer, J., Taylor, K.L., Hewitt, J.A., Quinn, C.P., Nuzum, E.O.
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5130595/
https://ncbi.nlm.nih.gov/pubmed/27558619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2016.06.041
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items